Johnson & Johnson (NYSE:JNJ) subsidiary Animas Corp. warned European regulators that certain of the company’s ambulatory insulin pumps contain a software flaw that will render the devices defunct on the stroke of midnight on December 31, 2015.
Insulin Management
Medtronic asks court to strike insulin pump fraud case | MassDevice.com On Call
Diabetes: Insulet lands FDA clearance for next-gen OmniPod insulin pump
CeQur lands CE Mark for its PaQ continuous insulin delivery device
CeQur SA received CE Mark approval to commercialize its PaQ insulin delivery devices in the European market, the company reported this week.
The PaQ insulin delivery system features a disposable insulin-infuser reservoir attached to a reusable insulin monitor and provides 3 days of continuous basal insulin delivery and on-demand bolus insulin for individuals with Type II diabetes, the company said.
More legal troubles for Medtronic?
Medtronic (NYSE:MDT) may have found itself in another bind with the U.S. Justice Dept., according to the medical device giant’s latest financial report.
In August 2011 the company received a DoJ request for more information about insulin pump replacements for Medicare beneficiaries, Medtronic reported. The device maker is "fully cooperating with this inquiry."
Medtronic did not respond to requests for comment.
Medtronic diabetes devices merge with Bayer’s new glucometer | MassDevice.com On Call
Diabetes: Insulet gains on Q2 results
Diabetes: Progress in artificial pancreas could save Medicare nearly $1B | MassDevice.com On Call
MASSDEVICE ON CALL — Artificial pancreas technology for monitoring and moderating symptoms of diabetes could help save the U.S. healthcare system $937 million over 25 years, according to a new study.
The technology, which would combine an automated blood glucose monitor and insulin delivery system, could help prevent diabetic patients from experiencing complications associated with their disease, the researchers wrote.
Diabetes: Roche wins FDA nod for combo glucose meter and insulin pump
Roche (PINK:RHHBY) touted a new win for its Accu-Chek line of diabetes management devices, this time for the Combo system which unites a blood glucose meter and an insulin pump.
The meter and pump can seamlessly transmit data back and forth via Bluetooth, allowing for remote insulin delivery and providing guidance on dosage levels.
Diabetes: J&J’s artificial pancreas proves effective in 1st human clinical trials
A 1st-generation artificial pancreas by Johnson & Johnson (NYSE:JNJ) subsidiary Animas Corp. proved successful in managing inulin levels in patients with Type I diabetes, researchers unveiled over the weekend at the annual American Diabetes Assn. meeting in Philadelphia.